Journal article

Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial

FM Russell, JR Carapetis, A Balloch, PV Licciardi, AWJ Jenney, L Tikoduadua, L Waqatakirewa, J Pryor, J Nelson, GB Byrnes, YB Cheung, MLK Tang, EK Mulholland

VACCINE | ELSEVIER SCI LTD | Published : 2010

Grants

Funding Acknowledgements

The authors wish to sincerely thank all the FIPP staff and families participating in the study, and the many other people who contributed to the study including: Amanda O'Brien, Kathryn Bright, Samantha Colquhoun, Amy Bin Chen, Timothy Gemetzis, Amy Auge, Katherine Gilbert, Evan Willis, Philip Greenwood, Beth Temple, Vanessa Johnston, Loretta Thorn, Porter Anderson, Brian Greenwood, George Siber, David Klein, Elizabeth Horigan, and Farukh Khambaty. The authors wish to thank the DSMB members. Pneumovax (TM) was kindly donated by CSL Biotherapies, Australia. The co-administered Tritanrix (TM)-HepB (TM) and Hiberix (TM) vaccines were kindly donated by GlaxoSmithKline. Conflicts of interest. MLT has been a consultant/advisor for Wyeth. The other authors declared no conflicts of Interest. Funding: Funding was provided by the U.S. NIAID and the Australian National Health and Medical Research Council. Trials registration. Clinical Trial Registry, National Library of Medicine, USA. Clinical trial number: NCT00170612.